Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes.

Timothy P FosterMichael J HallerBrittany BruggemanChelsea SalmonJennifer HosfordAngela ChenMiriam CintronClayton E MathewsClive WasserfallMaigan A BruskoTodd M BruskoMark A AtkinsonDesmond A SchatzMichael J Haller

Published in: Diabetes care (2024)

These observations support additional prospective studies evaluating ATG in stage 2 type 1 diabetes.

Keyphrases

type diabetes
low dose
glycemic control
cardiovascular disease
insulin resistance
high dose
study protocol
clinical trial
case control
skeletal muscle